


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound according to Formula (1):

~~In one aspect of the present invention, there is provided a compound of formula (1):~~



wherein:

R is selected from the group consisting of:

C₂₋₆ alkyl (optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl); ~~C₂₋₆ alkenyl (optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl); C₂₋₆ alkynyl (optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl);~~ (CH₂)_n—C₃₋₆ carbocycle (optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl); and (CH₂)_n—R₂, wherein R₂ is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R₂ is optionally substituted by one or more substituent selected from Cl, Br, I, C₁₋₃ alkyl (optionally substituted by one to three F) and C₁₋₂ alkoxy (optionally substituted by one to three F));


R₁ is selected from the group consisting of aryl and heteroaryl;

Y represents Θ , CH₂ or a covalent bond; and

n is an integer from 0 to 2;

or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

2. (Currently amended) A compound according to claim 1, with the following absolute configuration:



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

3. (Currently amended) A compound according to claim 3 selected from the group consisting of:

Quinoline-8-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

1,2,3,4-Tetrahydro-quinoline-8-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

Benzofuran-2-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

Quinoline-6-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

1,2,3,4-Tetrahydro-quinoline-6-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

7-Methoxy-benzofuran-2-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

5-Methoxy-benzofuran-2-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino)-methyl)-amide[.];

3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[.];

5-Trifluoromethyl-furan-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[.];

3,4-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-benzamide[.];

2,3-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-benzamide.

[1,8]Naphthyridine-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[.];

3-Methyl-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[.];

Benzo[1,3]dioxole-5-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[.];

Benzofuran-2-carboxylic acid {(R)-2-cyclopentylmethyl-3-(formyl-hydroxy-amino)-propanoylamino]-methyl)-amide[.]; and

Benzofuran-2-carboxylic acid ({(R)-7,7,7-trifluoro-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide; or a pharmaceutically acceptable salt thereof.

4. (Canceled)

5. (New) A pharmaceutical composition comprising a compound according claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

6. (New) A pharmaceutical composition comprising a compound according claim 3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.